TRex Bio closed at $13.55 on Nov 2, down 1.38%, within 0.4% of its lowest close since Oct 9. Volume of 38.6K shares was 0.22× its 20-day average (below normal).
Short interest was 195.6K shares at the Oct 15 settlement (1.4% of float, 1.1 days to cover).
Trex Bio Inc is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases.
What is TRXB's market cap?
$371.89M, based on the Nov 2 close of $13.55.
How much of TRXB is sold short?
195.6K shares, 1.4% of float, as of Oct 15, 2026.
About TRex Bio
Trex Bio Inc is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology